AU753336B2 - Use of alkylated iminosugars to treat multidrug resistance - Google Patents

Use of alkylated iminosugars to treat multidrug resistance Download PDF

Info

Publication number
AU753336B2
AU753336B2 AU12973/99A AU1297399A AU753336B2 AU 753336 B2 AU753336 B2 AU 753336B2 AU 12973/99 A AU12973/99 A AU 12973/99A AU 1297399 A AU1297399 A AU 1297399A AU 753336 B2 AU753336 B2 AU 753336B2
Authority
AU
Australia
Prior art keywords
dideoxy
imino
galactitol
glucitol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU12973/99A
Other languages
English (en)
Other versions
AU1297399A (en
Inventor
Gary S. Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU1297399A publication Critical patent/AU1297399A/en
Application granted granted Critical
Publication of AU753336B2 publication Critical patent/AU753336B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU12973/99A 1997-11-10 1998-11-09 Use of alkylated iminosugars to treat multidrug resistance Ceased AU753336B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6505197P 1997-11-10 1997-11-10
US60/065051 1997-11-10
PCT/US1998/023239 WO1999024401A1 (en) 1997-11-10 1998-11-09 Use of alkylated iminosugars to treat multidrug resistance

Publications (2)

Publication Number Publication Date
AU1297399A AU1297399A (en) 1999-05-31
AU753336B2 true AU753336B2 (en) 2002-10-17

Family

ID=22060028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12973/99A Ceased AU753336B2 (en) 1997-11-10 1998-11-09 Use of alkylated iminosugars to treat multidrug resistance

Country Status (15)

Country Link
US (1) US6225325B1 (enExample)
EP (1) EP1030839B1 (enExample)
JP (1) JP2001522833A (enExample)
AR (1) AR018732A1 (enExample)
AT (1) ATE258919T1 (enExample)
AU (1) AU753336B2 (enExample)
CA (1) CA2309321A1 (enExample)
DE (1) DE69821520T2 (enExample)
DK (1) DK1030839T3 (enExample)
ES (1) ES2216327T3 (enExample)
MY (1) MY122499A (enExample)
PT (1) PT1030839E (enExample)
TW (1) TW581677B (enExample)
WO (1) WO1999024401A1 (enExample)
ZA (1) ZA9810210B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029321A1 (en) 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000056334A1 (en) * 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
ES2302697T3 (es) * 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
GB0006539D0 (en) * 2000-03-17 2000-05-10 Oxford Glycosciences Uk Ltd Therapies
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
US7985760B2 (en) 2002-07-17 2011-07-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
PT1594544T (pt) * 2003-01-31 2016-07-14 Los Angeles Childrens Hospital Composições orais de fenretinida tendo biodisponibilidade aumentada e métodos de utilização das mesmas
EP1597231A1 (en) * 2003-02-20 2005-11-23 Ranbaxy Laboratories, Ltd. Derivatives of azasugars as anticancer agents
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US8975280B2 (en) 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
CN102427804A (zh) 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CN105246478A (zh) 2013-03-15 2016-01-13 优尼特尔病毒学公司 抗菌化合物
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
KR102747683B1 (ko) 2015-12-30 2024-12-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
ES2950808T3 (es) 2017-05-15 2023-10-13 Amicus Therapeutics Inc Alfa-glucosidasa ácida humana recombinante
US12612380B2 (en) 2019-05-10 2026-04-28 Alectos Therapeutics 1Nc Non-lysosomal glucosylceramidase inhibitors and uses thereof
US12528773B2 (en) 2020-05-07 2026-01-20 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
KR20230008826A (ko) * 2020-05-07 2023-01-16 알렉토스 테라퓨틱스 인크. 비-리소좀 글로코실세라미다아제 억제제 및 이의 용도
WO2025017212A1 (en) * 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452406A (en) 1891-05-19 Hanger for pictures
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3049446A1 (de) 1980-12-30 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,5-didesoxy-1,5-imino-d-glucitol und dessen n-derivaten
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
JPS63501925A (ja) 1985-12-23 1988-08-04 フレツド　ハツチンソン　キヤンサ−　リサ−チ　センタ− レトロウイルスの複製、感染及び疾病誘発の制御
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
ES2108680T3 (es) * 1987-12-21 1998-01-01 Monsanto Co Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
EP0350012A3 (en) 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
US5003072A (en) 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US5144037A (en) 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US4957926A (en) 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5151519A (en) 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
ES2087277T3 (es) 1990-09-20 1996-07-16 Monsanto Co Procedimiento para producir 1-desoxinojirimicina n-sustituida.
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
IL105090A (en) 1992-03-18 1998-08-16 Us Bioscience Acid N) phosphonoacetyl (Aspartic L in a broad spectrum antiviral agent
US5331096A (en) 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5258518A (en) * 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
EP0655457A1 (en) 1992-08-14 1995-05-31 Nippon Shinyaku Company, Limited Moranoline derivative
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
DE69421828T2 (de) 1994-01-13 2000-04-20 G.D. Searle & Co. Verwendung von 1,5-dideoxy-1,5-imino-d-glucitol n-alkylderivaten zur behandlung von hepatitis b infektionen
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
WO1997000881A1 (fr) 1995-06-22 1997-01-09 Nippon Shinyaku Co., Ltd. Derives de la moranoline
DE69830241T2 (de) 1997-02-14 2006-01-26 G.D. Searle Llc, Chicago Verwendung von n-substituierten 1,5-dideoxy-1,5-imino-d-glucitol verbindungen in der kombinationstherapie der vom hepatitisvirus verursachten infektionen

Also Published As

Publication number Publication date
AU1297399A (en) 1999-05-31
WO1999024401A1 (en) 1999-05-20
DE69821520T2 (de) 2004-12-16
AR018732A1 (es) 2001-12-12
TW581677B (en) 2004-04-01
CA2309321A1 (en) 1999-05-20
JP2001522833A (ja) 2001-11-20
MY122499A (en) 2006-04-29
ES2216327T3 (es) 2004-10-16
DK1030839T3 (da) 2004-05-03
ATE258919T1 (de) 2004-02-15
PT1030839E (pt) 2004-05-31
EP1030839B1 (en) 2004-02-04
US6225325B1 (en) 2001-05-01
ZA9810210B (en) 1999-07-14
EP1030839A1 (en) 2000-08-30
DE69821520D1 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
EP1030839B1 (en) Use of alkylated iminosugars to treat multidrug resistance
AU2023229524B2 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
EP4010329B1 (en) Deuterated compounds for use in the treatment of cancer
KR102125661B1 (ko) 전립선암 치료용 조합, 약학 조성물 및 치료 방법
EP1210082B1 (en) Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions
JP2021011495A (ja) 抗増殖性化合物及びその使用方法
EP3673907A1 (en) Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
KR102272274B1 (ko) (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온의 제제
US6265427B1 (en) Pharmaceutical composition for the method of treating leukemia
US6747061B2 (en) N-substituted dithiocarbamates for the treatment of biological disorders
CN112839658B (zh) 用于治疗癌症的组合疗法
CN115867551A (zh) 单一疗法和组合疗法
JP2017521396A (ja) 癌のための併用療法
KR20250003774A (ko) 신규 gspt1 화합물 및 신규 화합물의 사용 방법
EP3878444B1 (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
JP5595278B2 (ja) オピオイド拮抗薬による薬物誘発性嘔気の治療
US20220267350A1 (en) Adenosine receptor antagonist
EP4473966A1 (en) Cancer treatment agent including malt1 inhibiting drug as active ingredient
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
US20070037783A1 (en) Migrastatin analogs and uses thereof
AU2021303438B2 (en) Combination of a methionine aminopeptidase 2 inhibitor and VEGFR/VEGF inhibitor
EP2228365A1 (en) Pharmaceutical combination of 5-fluorouracil and derivative of 1,4-dihydropyridine and its use in the treatment of cancer
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40076656A (en) Deuterated compounds for use in the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)